Kolexia
Lagneau Edouard Oncologie radiothérapie
Lagneau Edouard
Oncologie radiothérapie
Hopital Prive Sainte Marie
Chalon-sur-Saône, France
45 Activités
12 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Tumeurs prostatiques résistantes à la castration Métastase tumorale Tumeurs du cerveau Fatigue Glioblastome {{person.topmesh8.name}} {{person.topmesh9.name}} {{person.topmesh10.name}}

Collaborateurs

Voir plus
Chambade Damien
Chambade Damien
Centre Georges-François Leclerc, Dijon, France
Darut-Jouve Ariane
Darut-Jouve Ariane
Clinique Mutualiste Benigne Joly, Talant, France
Lepinoy Alexis
Lepinoy Alexis
Hopital Prive Sainte Marie, Chalon-sur-Saône, France
Foahom Kamwa Alain
Foahom Kamwa Alain
Clinique Mutualiste Benigne Joly, Talant, France

Industries

Voir plus
MSD
8 collaboration(s)
Dernière en 2023
Ipsen
5 collaboration(s)
Dernière en 2020
Bayer
4 collaboration(s)
Dernière en 2023
AstraZeneca
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
GETUG-AFU 22 Phase II Randomized Trial Evaluating Outcomes of Post-Operative Immediate Salvage Radiation Therapy with or without ADT for Patients with Persistently Elevated PSA Level
A Red Journal Special IssueOligometastasis, Part 2   01 décembre 2022
Combining androgen deprivation and radiation therapy in the treatment of localised prostate cancer: Summary of level 1 evidence and current gaps in knowledge.
Clinical and translational radiation oncology   21 juillet 2022
Late toxicity and quality of life from GETUG-AFU 22 study.
2020 Genitourinary Cancers Symposium   19 février 2020
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
European urology   05 octobre 2019
Late Toxicity and Quality of Life from GETUG-AFU 22 Study: A Multicenter Randomized Phase II Trial Comparing Radiotherapy +/- 6 Months of Degarelix as a Salvage Treatment for Patients with Detectable PSA after Radical Prostatectomy
Proceedings of the Amercian Society for Radiation Oncology 61st Annual Meeting   01 septembre 2019
AQUARiUS: Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patients
Essai Clinique (Janssen)   23 mai 2019
7 Phantom LEGO® Vs CT4D
Abstracts of the 57èmes Journées Scientifiques de la Société Française de Physique Médicale   01 décembre 2018
Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study.
ESMO open   03 août 2018
Initial results from AQUARiUS, a prospective, observational, multi-centre phase IV study assessing patient-reported outcomes (PROs) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate plus prednisone (AAP) or enzalutamide (ENZ)
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain   01 septembre 2017
The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy.
2017 Genitourinary Cancers Symposium   29 mars 2017